Clinical Trials Directory

Trials / Sponsors / Dynavax Technologies Corporation

Dynavax Technologies Corporation

Industry · 25 registered clinical trials2 currently recruiting.

StatusTrialPhaseStarted
RecruitingImmunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis
Phase 22025-09-11
RecruitingSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Health
Shingles, Herpes Zoster, Vaccine-Preventable Diseases
Phase 1 / Phase 22024-06-17
CompletedTrial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF
Plague, Pneumonic, Plague, Vaccine-Preventable Diseases
Phase 22022-08-09
CompletedTrial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-
Shingles, Herpes Zoster, Vaccine-Preventable Diseases
Phase 12022-01-10
UnknownDV2-HBV-27: Observational Pregnancy Registry
Pregnant
2021-02-21
CompletedHEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
End Stage Renal Disease on Hemodialysis (Diagnosis)
Phase 12019-04-22
CompletedPhase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
Advanced Non Small Cell Lung Cancer
Phase 12017-09-20
TerminatedA Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Mel
Metastatic Melanoma, Head Neck Cancer
Phase 1 / Phase 22015-09-01
TerminatedStudy of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell L
B-cell Lymphoma
Phase 1 / Phase 22014-10-01
CompletedSafety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine
Healthy
Phase 32014-04-01
CompletedA Study of the Immune Response to Heplisav in Healthy Older Adults
Hepatitis B
Phase 12013-11-01
CompletedLong-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease
Chronic Kidney Disease
2010-12-01
CompletedSafety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis
End Stage Renal Disease
Phase 32010-12-01
CompletedSafety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine
Healthy
Phase 32010-02-01
CompletedA Study to Assess DV-601 in Subjects With Chronic Hepatitis B
Hepatitis B, Chronic
Phase 12009-09-01
CompletedComparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients
Chronic Kidney Disease
Phase 32009-09-01
CompletedSafety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepat
Chronic Hepatitis C
Phase 12008-10-01
CompletedSafety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males
Healthy
Phase 12008-01-01
CompletedAn Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposur
Rhinitis, Allergic, Seasonal
Phase 22007-09-01
TerminatedA Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Sta
Hepatitis B
Phase 22007-07-01
CompletedOpen-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine
Hepatitis B
Phase 22007-06-01
CompletedSafety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine
Hepatitis B
Phase 32006-12-01
TerminatedA Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients
Colorectal Neoplasms
Phase 12006-11-01
TerminatedEfficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults
Rhinitis, Allergic, Seasonal
Phase 22006-04-01
CompletedSafety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients
Hepatitis B
Phase 12006-01-01